Skip to main content
Links to homepage of ULTOMIRIS patient site

Call us at 1-877-GMG-ULTO (877-464-8586)


Frequently Asked Questions

About gMG:

What is gMG?

Generalized myasthenia gravis (gMG) is an autoimmune disease that damages the communication between your nerves and muscles. It is estimated that over 71,000 people in the United States are living with anti-acetylcholine receptor (AChR) antibody-positive gMG, which is the specific type of gMG that ULTOMIRIS is approved to treat.

Learn more about gMG

What are the most common symptoms of gMG?

Common gMG symptoms include muscle weakness that may lead to trouble with arm or leg strength, talking or chewing, and other basic daily functions. Stress, changes in the weather, and using your muscles throughout the day may trigger gMG symptoms, which can occur at any time and make daily planning difficult.

Learn more about gMG symptoms

How is gMG diagnosed?

Everyone’s journey toward their gMG diagnosis is different, but many people report feeling limited by their symptoms, which can impact daily routines and activities. If you think that you might have gMG, you can use the questionnaire below to track your gMG symptoms and start a conversation with your doctor at your next visit.

Download the gMG symptom questionnaire


Is ULTOMIRIS right for me?

ULTOMIRIS is indicated for the treatment of adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. If you still feel limited by your gMG symptoms, even after treatment, consult your doctor to see if ULTOMIRIS may be right for you. You can use the questionnaire below to track your gMG symptoms and start a conversation with your doctor at your next visit.

Download the gMG symptom questionnaire

How is ULTOMIRIS thought to work?

ULTOMIRIS is proven to bind to and block C5, a protein within a part of your immune system called “complement.” Though the exact way that ULTOMIRIS works is unknown in gMG, complement is known to incorrectly attack your muscles and contribute to the gMG symptoms that you may experience.

Learn more about how ULTOMIRIS works

How was ULTOMIRIS studied?

ULTOMIRIS was studied in a clinical trial (CHAMPION-MG) that included 175 adults with varying degrees of severity of anti-AChR antibody-positive gMG. The trial measured the impact of ULTOMIRIS through improvements in participants’ daily activities and muscle weakness. Over 90% of people in the trial had mild or moderate gMG, and most were taking an immunosuppressive therapy when they first started taking ULTOMIRIS.

Learn more about how ULTOMIRIS was studied

How can ULTOMIRIS help me manage my gMG?

In a clinical trial, ULTOMIRIS was proven to reduce the impact of gMG symptoms on activities of daily living. ULTOMIRIS was also proven to reduce muscle weakness, improving physical functions such as seeing, talking, and swallowing.

Learn more about how ULTOMIRIS may help

How do I take ULTOMIRIS and what are the dosing requirements?

ULTOMIRIS is given via intravenous infusion by a healthcare professional at an infusion center or doctor's office. Starting 2 weeks after your initial dose, ULTOMIRIS offers predictable maintenance dosing just once every 8 weeks. If you have not already had them, you must receive vaccines for meningococcal infection at least 2 weeks before your first dose of ULTOMIRIS. Your healthcare provider or nurse will make sure you receive these vaccines at least 2 weeks before your first infusion.

Learn more about ULTOMIRIS dosing

What are the side effects of ULTOMIRIS?

Side effects were studied in the ULTOMIRIS clinical trial (CHAMPION-MG). The most common side effects reported in ≥10% of people receiving ULTOMIRIS were diarrhea and upper respiratory tract infection. In the trial, only 2 people taking ULTOMIRIS stopped treatment due to side effects compared to 3 people taking placebo.

Learn more about side effects of ULTOMIRIS

Can I receive ULTOMIRIS while pregnant or breastfeeding?

There are currently no available data on the use of ULTOMIRIS in pregnant women or on the presence of ULTOMIRIS in human milk. If you are pregnant, you should consult with your doctor before receiving ULTOMIRIS. Breastfeeding should be discontinued during treatment with ULTOMIRIS and for 8 months after the final dose.

What support is available for people on ULTOMIRIS?

If you are on ULTOMIRIS, you can take advantage of OneSource™, a free, personalized patient support program offered by Alexion. Get help with insurance coverage, answers to questions about your treatment with ULTOMIRIS, access to community resources, and more.

Learn more about OneSource

How can I get started on ULTOMIRIS?

Getting started on ULTOMIRIS is simple with 3 easy steps . Learn how to connect with a doctor and prepare for what you may expect while on ULTOMIRIS.

Learn how to get started on ULTOMIRIS

How can I afford ULTOMIRIS?

Alexion is committed to helping you afford ULTOMIRIS. While your out-of-pocket cost for ULTOMIRIS may vary, Alexion’s OneSource patient support program can provide help with navigating insurance matters and eligibility for financial assistance.

Learn more about OneSource

Is there a way for me to connect with other people on ULTOMIRIS?

Alexion hosts webinars and events for people with gMG so that they have the opportunity to hear from leading doctors and to learn from other people receiving ULTOMIRIS.

Join our events

About transitioning from SOLIRIS® (eculizumab):

How is ULTOMIRIS different from SOLIRIS?

ULTOMIRIS is built on the foundation of SOLIRIS. Both treatments bind to and block complement protein C5, but ULTOMIRIS is designed to last longer so that you only need a maintenance dose once every 8 weeks, starting 2 weeks after your initial dose.

If I’m already taking SOLIRIS and want to transition to ULTOMIRIS, what should I do?

Talk to your doctor about making the transition to ULTOMIRIS. Transitioning from SOLIRIS to ULTOMIRIS should be done at the discretion of your doctor, who will use their clinical judgment in deciding the appropriate course of action.


Have any additional questions? Call us at 1-877-GMG-ULTO (877-464-8586)

Receive information & updates


What is the most important information I should know about ULTOMIRIS?
ULTOMIRIS is a medicine that affects your immune system and can lower the ability of your immune system to fight infections.

  • ULTOMIRIS increases your chance of getting serious and life-threatening meningococcal infections that may quickly become life-threatening and cause death if not recognized and treated early.
  1. You must receive meningococcal vaccines at least 2 weeks before your first dose of ULTOMIRIS if you are not vaccinated.
  2. If your healthcare provider decided that urgent treatment with ULTOMIRIS is needed, you should receive meningococcal vaccination as soon as possible.
  3. If you have not been vaccinated and ULTOMIRIS therapy must be initiated immediately, you should also receive 2 weeks of antibiotics with your vaccinations.
  4. If you had a meningococcal vaccine in the past, you might need additional vaccination. Your healthcare provider will decide if you need additional vaccination.
  5. Meningococcal vaccines reduce but do not prevent all meningococcal infections. Call your healthcare provider or get emergency medical care right away if you get any of these signs and symptoms of a meningococcal infection: headache with nausea or vomiting, headache and fever, headache with a stiff neck or stiff back, fever, fever and a rash, confusion, muscle aches with flu-like symptoms and eyes sensitive to light.

Your healthcare provider will give you a Patient Safety Card about the risk of meningococcal infection. Carry it with you at all times during treatment and for 8 months after your last ULTOMIRIS dose. It is important to show this card to any healthcare provider or nurse to help them diagnose and treat you quickly.

ULTOMIRIS is only available through a program called the ULTOMIRIS REMS. Before you can receive ULTOMIRIS, your healthcare provider must: enroll in the ULTOMIRIS REMS program; counsel you about the risk of meningococcal infection; give you information and a Patient Safety Card about the symptoms and your risk of meningococcal infection (as discussed above); and make sure that you are vaccinated with a meningococcal vaccine, and if needed, get revaccinated with the meningococcal vaccine. Ask your healthcare provider if you are not sure if you need to be revaccinated.

ULTOMIRIS may also increase the risk of other types of serious infections. Call your healthcare provider right away if you have any new signs or symptoms of infection.

Who should not receive ULTOMIRIS?
Do not receive ULTOMIRIS if you have a meningococcal infection or have not been vaccinated against meningococcal infection unless your healthcare provider decides that urgent treatment with ULTOMIRIS is needed.

Before you receive ULTOMIRIS, tell your healthcare provider about all of your medical conditions, including if you: have an infection or fever, are pregnant or plan to become pregnant, and are breastfeeding or plan to breastfeed. It is not known if ULTOMIRIS will harm your unborn baby or if it passes into your breast milk. You should not breastfeed during treatment and for 8 months after your final dose of ULTOMIRIS.

Tell your healthcare provider about all the vaccines you receive and medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements which could affect your treatment.

What are the possible side effects of ULTOMIRIS?
ULTOMIRIS can cause serious side effects including infusion-related reactions. Symptoms of an infusion-related reaction with ULTOMIRIS may include lower back pain, tiredness, feeling faint, discomfort in your arms or legs, bad taste, or drowsiness. Stop treatment of ULTOMIRIS and tell your healthcare provider or nurse right away if you develop these symptoms, or any other symptoms during your ULTOMIRIS infusion that may mean you are having a serious infusion reaction, including: chest pain, trouble breathing or shortness of breath, swelling of your face, tongue, or throat, and feel faint or pass out.

The most common side effects of ULTOMIRIS in people with gMG are diarrhea and upper respiratory tract infections.

Tell your healthcare provider about any side effect that bothers you or that does not go away. These are not all the possible side effects of ULTOMIRIS. For more information, ask your healthcare provider or pharmacist. Call your healthcare provider right away if you miss an ULTOMIRIS infusion or for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


ULTOMIRIS is a prescription medicine used to treat adults with a disease called generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

It is not known if ULTOMIRIS is safe and effective for the treatment of gMG in children.

Please see the full Prescribing Information and Medication Guide for ULTOMIRIS, including Boxed WARNING regarding serious and life-threatening meningococcal infections/sepsis.

Questions? Call us at 1-877-GMG-ULTO (877-464-8586)